VCG
MYGN icon

Vantage Consulting Group’s Myriad Genetics MYGN Stock Holding History

Vantage Consulting Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,258
Closed -$25K – 1025
2020
Q4 		$25K Buy
+1,258
New +$20.3K ﹤0.01% 779

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Vantage Consulting Group's MYGN Position: Q1 2021 in Review

Vantage Consulting Group sold out of Myriad Genetics (MYGN) in Q1 2021, closing a stake of 1,258 shares — an estimated $25K sold.

Vantage Consulting Group first reported a position in MYGN in Q4 2020 and held it in 1 quarter. The position peaked at $25K in Q4 2020. 197 funds tracked by Wall St. Rank hold MYGN as of Q1 2021.

  • Vantage Consulting Group reported no remaining Myriad Genetics position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 1,258 Myriad Genetics shares in Q1 2021, an estimated $25K.
  • Vantage Consulting Group first reported a position in Myriad Genetics in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Myriad Genetics position peaked at $25K in Q4 2020.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.